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Accepted 26 June 2016Background: The impact of chromosomal 1p/19q co-deletion on the prognosis of oligodendrogliomas has been
measured inmany studies previously. Howevermost studies used 1p/19q co-deletion as a covariate to be adjust-
ed for in a multivariable model that aimed to assess treatment effects, thus not directly measuring the effect of
the 1p/19q co-deletion on prognosis.We conducted a systematic review andmeta-analysis to synthesize the re-
sults and provide insight on how 1p/19q co-deletion affects prognoses of WHO grade II/III oligodendrogliomas.
Methods:Weightedmeandifference (WMD), standardizedmean difference (SMD), andhazard ratios (HRs)were
used to report pooled effect of 1p/19q co-deletion on prognosis of oligodendrogliomas. The Meta-ANOVAmodel
was used to obtain the pooled HRs.
Results: The difference inmedian overall survival (OS) time is 0.24 (95% CI: 0.15 to 0.33) and theWMD for 5-year
OS rate is 6.87% (95% CI: 6.66% to 7.07%), favoring patients with co-deletion. The pooled hazard ratio (HR) for
mortality is 0.28 (95% CI: 0.13 to 0.62), favoring 1p/19q co-deletion. For progression free survival (PFS), the
SMD ofmedian PFS time is 0.13 (95% CI: 0.04 to 0.21), in favor of 1p/19q co-deletion.When comparing therapies
among patients with 1p/19q co-deletion, we found that those receiving radiation therapy (RT) and chemother-
apy (CT) had a signiﬁcantly better prognosis than those who received RT only, with pooled HR of 0.64 (95% CI:
0.51 to 0.80).
Conclusions:Our pooled results show that chromosomal 1p/19q co-deletion has a signiﬁcant protective effect on
prognosis of grade II/III oligodendrogliomas.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Oligodendrogliomas are a rare primary brain tumor [1]. The world
health organization (WHO) rates these tumors as low grade (grade II)
or high grade/anaplastic (grade III). Grade II tumors may evolve into
grade III tumors over time [2]. The incidence of oligodendrogliomas, in-
cluding anaplastic oligodendrogliomas, is approximately 0.3 per
100,000 people in the United States [3]. Deletion and co-deletion of
chromosome 1p/19q occurs in 50% to 70% of WHO grade II and III
oligodendrogliomas found in the United States [3]. The chromosomal
1p/19q co-deletion has been shown to be an important control factoree survival; SMD, standardized
R, hazard ratio; CI, conﬁdence
, 2000 Circle of Hope, Salt Lake
. This is an open access article underof overall survival (OS) and progression free survival (PFS) in previous
clinical studies that examined therapy effects on survival using multi-
variable models [4,5]. Patients with 1p/19q co-deletions have also
been shown to have longer OS and PFS regardless of the treatment
they receive [4,5].
Since oligodendrogliomas are rare diseases, the need for a meta-
analysis exists in order to better estimate the effect of chromosomal
1p/19q co-deletion on their prognosis such as OS and PFS. We sought
to investigate the effect of 1p/19q co-deletion, as a predictor, on OS
and PFS. Most previous studies used the molecular structure of 1p/19q
co-deletion as a covariate to be adjusted for in multivariable analyses
when assessing the effect of treatment. Consequently, the effect of 1p/
19q co-deletion as an exposure on the prognosis of oligodendrogliomas
is not explicit. In this meta-analysis, we use the Meta-ANOVA method
[6] to evaluate the effect of 1p/19q co-deletion on OS and PFS by synthe-
sizing the results in multivariable analyses in previous studies.
Oligodendrogliomas are known to be chemo-sensitive and respond
positively to treatment although the best treatment for these types ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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therapy (RT) alone and RT in combination with chemotherapy (CT). In
this systematic review and meta-analysis, we also provide the pooled
results that compare the survival between RT alone and RT combined
with CT among oligodendroglioma patients with 1p/19q co-deletion.
Our study selects literature for patients diagnosed with both WHO
grade II and III oligodendrogliomas.
2. Material and methods
This study was conducted in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
standards [8].
2.1. Literature search
The electronic databases PubMed, Medline, and Embase were
searched to ﬁnd prospective articles to be included in our meta-
analysis. Key words and phrases used to ﬁnd potential articles were
“oligodendrogliomas”, “1p/19q” (or “1p19q”), “radiation therapy” and
“chemotherapy”. In addition, a search of abstracts presented at the
American Society of Clinical Oncology (ASCO) was also conducted
using the same search terms. Included studieswere published in English
from October 2005 to April 2014.
2.2. Inclusion criteria
Studies to be included in our meta-analysis met the following inclu-
sion criteria: (1) patients were clinically diagnosed with WHO grade II
or III oligodendrogliomas; (2) studies reported 1p/19q chromosome
co-deletion status; (3) studies reported the following information: OS,
PFS, use of surgery or adjuvant therapies (i.e., using both radiation ther-
apy and chemotherapy, or using only the radiation therapy). In cases
where studies published were updates of previous studies conductedFig. 1. Flow chart of the literature search strategy. The inclusion criteria are: (1) patients were
chromosomal 1p/19q co-deletion status; (3) reported the following outcomes of interest: OS, P
apy treatment, or only radiation therapy).involving the same study patient population, only the most recent pub-
lication was included in the analysis.
2.3. Data collection
Data was collected from each article by an abstractor (RR) and
reviewed by a second evaluator (NH) when needed. Data extraction
was done using a data abstraction sheet developed in Microsoft Excel.
The speciﬁc items we recorded in the Excel spreadsheet can be found
in the Supplemental Methods Section in the Supplementary Materials.
2.4. Statistical methods
The hazard ratios (HRs) and their conﬁdence intervals (CIs) from
each multivariable Cox regression model were collected as reported in
each article during the data extraction phase. One of the main issues
when combining effect sizes from separate Cox models is the concern
of how comparable they are. Each separate studymight adjust for a dif-
ferent set of covariates in the Cox model so the coefﬁcients could have
altered interpretations across studies [6]. To account for this, we con-
ducted a pooled analyses via Meta-ANOVA to evaluate the effect of 1p/
19q chromosomal co-deletion on OS and PFS. The pooled HRs obtained
from the Meta-ANOVA model was used to measure the effect. The de-
tails for using Meta-ANOVA method in our analysis can be found from
the Supplemental Methods section in Supplementary Materials.
The standardizedmeandifference (SMD) andweightedmeandiffer-
ence (WMD)were used to compare the OS/PFS rate at given time point
as well as the median OS/PFS time between patients with and without
1p/19q co-deletion [35]. The details for calculating SMDs and WMDs
in our analyses can be found from the Supplemental Methods section
in Supplementary Materials.
All statistical tests were two-sided, and a p-value lower than 0.05
was considered as statistically signiﬁcant. Data analyses were carried
out using Review Manager (Copenhagen, Denmark) [9], or RevMan,clinically diagnosed with WHO grade II and/or Grade III oligodendrogliomas; (2) reported
FS and use of surgery or adjuvant therapy (i.e., use both radiation therapy and chemother-
Table 1
Characteristics of all studies meeting study inclusion criteria.
Article Total sample size % of Males Source Country
Ahluwalia et al. [4] 62 52% Journal USA
Cairncross et al. [30] 291 60% Journal Canada
Minniti et al. [14] 84 56% Journal Italy
van den Bent et al. [16] 368 58% Journal Europe
Anderson et al. [17] 291 60% Journal North America
Gorlia et al. [31] 368 58% Journal Germany
Taal et al. [23] 53 72% Journal USA
Iwadate et al. [12] 25 60% Journal Japan
Iwadate et al. [24] 36 67% Journal Japan
Kim et al. [25] 33 45% Journal Korea
Lassman et al. [1] 1013 57% Journal USA
Gan et al. [7] 40 58% Journal Australia
Idbaih et al. [32] 45 56% Journal France
Kaloshi et al. [26] 30 67% Journal France
Kuo et al. [27] 49 55% Journal Taiwan
Mikkelsen [13] 48 60% Journal USA
van den Bent et al. [33] 165 – Journal Germany
Vogelbaum et al. [5] 39 54% Journal USA
Wick et al. [28] 274 58% Journal Germany
Giannini et al. [34] 247 – Journal USA
Brandes et al. [15] 67 58% Journal Italy
McLendon et al. [29] 46 – Journal USA
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(Stata Inc., College Station, TX, USA) version 14.
2.5. Assessment of heterogeneity
To check for heterogeneity, for each analysis we calculated the
pooled HR and SMD estimate using a random effects model. The I2 sta-
tistic tests the null hypothesis that each study is evaluating the same
effect.
2.6. Assessment of publication bias
Each pooled analysis outcome was qualitatively and quantitatively
assessed for publication bias using funnel plots and Egger's test,
respectively.
3. Results
3.1. Study characteristics
Our electronic database searches in PubMed, Medline, and Embase
resulted in a total of 276 articles initially. After removing duplicates
there were 209 articles remaining for screening. The screening process
further narrowed our results and removed 187 additional articles due
to not meeting inclusion criteria (3), reported in a language other than
English (19), single case report (11), having irrelevant data (35), litera-
ture review (98), or having outcomes reported in away thatwas not us-
able to our analysis (21). This left is with 22 studies that contributed to
our analysis (Fig. 1). Themedian andmean sample size of the 22 studies
was 58 and 167 respectively, and the average male to female ratio wasTable 2
Pooled effects (HRs and 95% Cis) on OS of chromosomal 1p/19q co-deletion and 1p/19q co-dele
methods (Meta-ANOVA and DerSimonian & Laird methods).
Meta-ANOVA
Pooled HR
1p/19q co-deletion 0.28
1p/19q co-deletion + no IDH-1 mutation 0.09
1p/19q co-deletion + total resection 0.19
1p/19q co-deletion + younger age (40-) 0.29
a By assuming the pooled Meta-ANOVA effect (log of HR) approximates to a Normal distrib58% to 42%. A total of 7 studies (32%) were conducted in the United
States. All included articles were published in peer-reviewed journals.
Table 1 lists each study and its characteristics in detail.
3.2. Overall survival
One study and 543 patients were found to compare the median OS
time between patients with chromosomal 1p/19q co-deletion and pa-
tients without co-deletion. The difference in median OS time and 95%
CI to be 0.24 year and (0.15 to 0.33) year, in favor of the chromosomal
1p/19q co-deletion.
Two studies and 91 patients were included in our pooled analysis of
the ﬁve year OS. We calculated the WMD to be 6.87% with a 95% CI
(6.65% to 7.08%), in favor of the co-deleted group. The obtained WMD
is statistically signiﬁcant at the 0.05 test level.
Nine studies and 2079 patients were included in our pooled analysis
of chromosomal 1p/19q co-deletion verses no deletion. Our pooled
analysis usedmultivariable and univariable time-to-eventmodels to es-
timate HRs and their 95% CI. We used both Meta-ANOVA [6] and the
DerSimonian and Laird (D&L) random effect estimator [10] that omits
covariates in the Cox models. Statistically, the estimated pooled effect
(in terms of logarithm of HR in Cox models) using D&L method is to
be biased towards zero if important covariates are omitted from the
model. Equivalently, the pooled HR ratios will be biased towards one.
The pooled effect estimated using Meta-ANOVA will signiﬁcantly re-
duce the bias. However, since the indicator variables for inclusion of co-
variates were included in the model, the variance estimates of the
pooled effectwill be larger than that estimated using the D&L estimator.
Table 2 presents the pooled effects (HRs their 95% CIs) on OS of 1p/19q
co-deletion and 1p/19q co-deletion together with another prognostic
factor (IDH-1 mutation, total resection and older age) by two methods
(Meta-ANOVA andD&L). TheMeta-ANOVAanalysis resulted in a pooled
HR of 0.28 (95% CI: 0.13 to 0.62), favoring patients with 1p/19q co-
deletion, adjusting for the covariates in the multivariable analyses, in-
cluding age, extent of resection, IDH-1 mutation and type of therapy
(radiation and chemotherapy versus chemotherapy only). This indi-
cates that 1p/19q co-deletion has a signiﬁcant protective effect on prog-
nosis of grade II and III oligodendrogliomas. Patients having 1p/19q
co-deletion and without IDH-1 mutation have a 91% reduction in the
hazard of death compared to patients without co-deletion and with
IDH-1mutation, after adjusting for age, extent of resection, and adjuvant
therapy, (HR = 0.09, 95% CI: 0.03 to 0.23). Similarly, the Meta-ANOVA
results give a pooled HR of 0.19 (95% CI: 0.06 to 0.55) for 1p/19q co-
deletion and total resection. This is to say, patients with 1p/19q co-
deletion and a total resection have an 81% reduction in hazard of
mortality compared to patients without both co-deletion and total
resection. Finally, the estimated Meta-ANOVA pooled effect on OS of
1p/19q co-deletion and older age (40+) is 0.29 (95% CI: 0.13 to 0.63).
That is, patients with 1p/19q co-deletion and younger age (less than
or equal to 40) have a 71% reduction in the hazard of death compared
to patients with no 1p/19q co-deletion and older than 40 years.
Two studies and 592 patientswere included in our pooled analysis of
chromosomal 1p/19q co-deletion verses no deletion for the univariable
analysis. Our meta-analysis for these studies resulted in a pooled HR oftion with another prognostic factor (IDH-1mutation, total resection and older age) by two
DerSimonian & Laird
95% CIa Pooled HR 95% CI
0.13–0.62 0.45 0.32–0.63
0.03–0.23 0.10 0.05–0.21
0.06–0.55 0.20 0.07–0.58
0.13–0.63 0.30 0.11–0.84
ution.
Fig. 2. Forest plot showing the pooled hazard ratio of mortality from univariable analysis for association between patients with chromosomal 1p/19q co-deletion and patients with no co-
deletion.
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sults were not signiﬁcant. The corresponding I2= 50%with a p-value of
0.16 indicating there could be heterogeneity. These results are most
likely due to the small number of studies included in this analysis, see
Fig. 2.
3.3. Progression free survival
Two studies and 591 patientswere included in our pooled analysis of
themedian PFS time. We calculated the SMD and 95% CI to be 0.13, and
(0.04 to 0.21) respectively, in favor of 1p/19q chromosome co-deletion.
There was no indication of heterogeneity as the estimated I2 = 0%
(p-value = 0.68), see Fig. 3.
Two studies and 77 patients were included in our pooled analysis of
the six-month and one year PFS rate. We calculated the WMD in PFS
rate at 6 months and 1 year to be 21.2% (95% CI: 20.9% to 21.3%) and
12.2% (95% CI: 12.0% to 12.4%) respectively, both statistically signiﬁcant
and in favor of chromosomal 1p/19q co-deletion.
3.4. Adjuvant therapies
Three studies and 1248 patients were included in our pooled analysis
comparing adjuvant therapies. We calculated the pooled HR to be 0.64
(95% CI: 0.51 to 0.80) respectively, in favor of radiation therapy and
chemotherapy compared to radiation therapy alone. There was no indi-
cation of serious heterogeneity across studies, I2 = 46%, p-value = 0.16,
see Fig. 4.
4. Discussion
We conducted a pooled analysis to measure the effect of the chromo-
somal 1p/19q co-deletion on prognostic outcomes, OS and PFS. In
previous literature, the 1p/19q co-deletion was considered as a
covariate in the multivariable models that assessed effect of treat-
ment, biomarkers and prognostic factors on survival outcomes of
oligodendroglioma [11–15]. To our best knowledge, systematic re-
views and meta-analysis of the effect of 1p/19q co-deletion on survival
outcomes have yet been conducted.
Based on twounivariable analysis on the effect of 1p/19q co-deletion
on OS, the pooled HR comparing 1p/19q co-deletion and intact was
found to be 0.64, in favor of the co-deletion patients. However, due to
the small number of available studies and the heterogeneity among
the studies, a large 95% CI (0.31 to 1.32) was obtained, which covers
the null value of 1 (Fig. 2). There was a lack of studies on the impactFig. 3. Forest plot showing the pooled effect of chromosomal 1p/19q co-deletion on PFS time. Th
deletion and patients with no co-deletion.of 1p/19q co-deletion, as an exposure, on OS and PFS, suggesting that
additional studies in the future are warranted.
We used the Meta-ANOVA [6] to estimate the effect of the 1p/19q
co-deletion. Our results of the effect of 1p/19q co-deletion on prognosis
of oligodendrogliomas are consistent with most of previous literature.
Our signiﬁcant ﬁndings of protective effect of 1p/19q co-deletion paral-
lel with those from the univariable analysis of Lassman et al., who ob-
tained an OS HR of 0.50 and 95% CI of (0.36 to 0.70), favoring 1p/19q
co-deletion [1].
The pooled results from the D&L random effects model tend to bias
the HR towards the null (i.e., HR = 1) but usually result in tighter CIs
due to the fact that no other covariates are included in themodel [6]. Al-
though the results from this traditional method are more efﬁcient, the
estimates do not accurately estimate the true effect. The Meta-ANOVA
method takes covariates into account, some of which might account
for confounding, and reduce if not eliminate bias, giving more accurate
estimates of the effect. When comparing our results from the Meta-
ANOVA to theD&Lmethod for patients having a 1p/19q co-deletion ver-
sus patients whodo not have a deletion, the subsequent HR (95% CI) are
0.28 (0.13 to 0.62) and 0.45 (0.32 to 0.63), respectively.
The SMD for themedian PFS was also found to be in favor of 1p/19q
co-deletion,with a pooled SMD of 0.13 (95% CI: 0.04 to 0.21). This result
is also comparable to that of Lassman et al., whose study found a protec-
tive and signiﬁcant effect of chromosomal 1p/19q co-deletion onmedi-
an PFS times [1].
Oligodendrogliomas are considered chemo-sensitive [7], our results
comparing patientswith the 1p/19q co-deletionwho received either ra-
diation therapy and chemotherapy or radiation therapy alone show a
statistically signiﬁcant pooled effect with pooled HR of 0.64 (95% CI:
0.51 to 0.80), favoring patients who received both radiation therapy
and chemotherapy. Previous studies, such as Van den Bent et al.,
found that among patients with the 1p/19q co-deletion, receiving radi-
ation therapy and chemotherapy resulted in longer OS timewhen com-
pared to those only receiving radiation therapy. In Van den Bent's study,
the HR was 0.75 (95% CI: 0.59 to 0.95) [16].
The type of studies in this meta-analysis is a mixture of randomized
studies and observational studies. Therefore, we conducted sensitivity
analyses for the Meta-ANOVA and the pooled hazard ratio for mortality
comparing 1p/19q co-deleted anaplastic oligodendroglioma patients
treated by RT and CT versus RT only, since both of themeta-analyses in-
cluded randomized and observational studies. For the meta-analysis of
therapies for 1p/19q co-deleted patients, we found the conclusion
drawn did not change across type of studies. The sub-analysis of non-
randomized studies gave a pooled hazard ratio of 0.58 (95% CI: 0.44–e plot shows the SMD inmedian PFS time between patientswith chromosomal 1p/19q co-
Fig. 4. Forest plot showing pooled hazard ratio of OS between radiation therapy (RT) and chemotherapy (CT) vs. RT alone among oligodendroglioma patients with 1p/19q co-deletion.
62 N. Hu et al. / Interdisciplinary Neurosurgery: Advanced Techniques and Case Management 5 (2016) 58–630.75), favoring patients treated by both RT and CT. The randomized
study provided hazard ratio of 0.75 (95% CI: 0.59–0.95), in favor of pa-
tient treated by both RT and CT. Although the randomized studies
gave a relative smaller effect, both type of studies were provide statisti-
cally signiﬁcant result, favoring patients treated by both therapies. For
the Meta-ANOVA model comparing the effect of 1p/19q co-deletion
on overall survival, we also found that the conclusion drawn did not
change across type of studies. Using all of the non-randomized studies,
the pooled HR of survival comparing 1p/19q co-deleted patients versus
non co-deletion patients from the Meta-ANOVA is 0.15 (95% CI: 0.05–
0.49). On the other hand, using all of the randomized studies, the pooled
HR is 0.42 (95% CI: 0.29–0.62).
In the non-randomized study conducted by Anderson and Mark
[17], patients were all diagnosed with anaplastic oligodendroglioma
(AO) with chromosomal 1p/19q co-deletion. The chemotherapy being
administered in the study was PCV. In another non-randomized study
by Lassman and colleagues [1], patients were diagnosedwith anaplastic
oligodendrogliomas or anaplastic oligoastrocytomas and were chromo-
somal 1p/19q co-deleted. The chemotherapy that was used in this
study contained included PCV and TMZ. In the recent randomized
study by van den Bent and colleagues [16], all patients were diagnosed
with anaplastic oligodendrogliomas, and the chemotherapy given to the
patients was PCV only. To the best of our knowledge, there has been
no report comparing efﬁcacy between the use of PCV and TMZ as
chemotherapeutic agents for anaplastic oligodendroglioma patient.
These two chemotherapies appear to be similar for anaplastic
oligodendroglioma patientwith 1p/19q co-deletion, in terms of efﬁcacy.
Thus, we believe that our meta-analysis comparing the survival of
oligiodendroglioma patients with 1p/19 co-deletion between RT + CT
and RT only would be informative and provide useful clinical evidence
on this issue.
One concernwhen comparing different studies is the accuracy of the
histological diagnosis [18]. Given that this meta-analysis is focused on
the effects of 1p/19q loss, we have the advantage of being quite certain
that the tumors being examined here are oligodendrogliomas. 1p19q
loss is found at a much higher rate in oligodendrogliomas compared
to astrocytomas or even mixed oligoastrocytomas [19–21]. Further-
more, when comparingmultiple studies, there are concerns of accurate-
ly distinquishing between grade II oligodendrogliomas and grade III
anaplastic oligodendrogliomas because of the subjective nature of the
WHO grading system for oligodendrogliomas. Histological differences
between grade II and III tumors relies on the ﬁnding of “signiﬁcant”
hypercellulariy and pleomorphism in the higher grade tumors [22]
that could introduce inter-observer variability between different pa-
thologists. This a limitation of this study but probably not a major
issue given that the inter-observer variability rate is most likely low
and randomly distributed across each study.
Our systematic review and meta-analysis has another two limita-
tions except for those mentioned above. First of all, in some of our
pooled analyses, the number of included studies is small, which may
lead to biased results although publication bias was not present in ourmeta-analyses. In addition, all of our analyses were conducted using ag-
gregated patient data (APA) since individual level data was not
available.
5. Conclusions
In conclusion, our results show the signiﬁcant protective effect chro-
mosomal 1p/19q co-deletion has on survival of patients with grade II
and III oligodendrogliomas. Patients with this co-deletion have signiﬁ-
cantly longer OS/PFS times compared to those without the co-
deletion. Patients with the co-deletion also are shown to have signiﬁ-
cantly longer OS times when treated with radiation therapy as well as
chemotherapy in comparison to radiation therapy alone. Results from
our pooled analysis using the Meta-ANOVA technique indicates that
the chromosomal 1p/19q co-deletion has a signiﬁcant protective effect
on OS and PFS among patients with grade II and III oligodendrogliomas
when important covariates are adjusted for.
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